SCHEMBL19217019

SCHEMBL19217019

Cc1[nH]c2ccccc2c1C1=C(c2ccccc2C(F)(F)F)C(=O)NC1=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 2/20 0.51
STK10 O94804 9/20 0.47
SLK Q9H2G2 9/20 0.47
JAK2 O60674 2/20 0.47
JAK1 P23458 2/20 0.47
JAK3 P52333 2/20 0.47
PRKCB P05771 2/20 0.45
PRKCA P17252 1/20 0.45
PRKCH P24723 1/20 0.45
PRKCE Q02156 1/20 0.45
PRKCQ Q04759 1/20 0.45
PRKCD Q05655 1/20 0.45
GSK3B P49841 1/20 0.44
CHEK1 O14757 1/20 0.44
WEE1 P30291 1/20 0.44
CCR6 P51684 1/20 0.44
HKDC1 Q2TB90 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17210889 0.84 CCR6 (0.43) CAMK2DSTK10SLKPRKCBPRKCA
SCHEMBL5686050 0.84 CAMK2D (0.57) CAMK2DPRKCBPRKCAPRKCHPRKCE
SCHEMBL15797048 0.83 GSK3B (0.49) CAMK2DSTK10SLKPRKCBPRKCA
SCHEMBL5682601 0.81 CAMK2D (0.54) CAMK2DSTK10SLKPRKCBPRKCA
SCHEMBL15797114 0.77 PRKCB (0.54) CAMK2DPRKCBPRKCAPRKCHPRKCE
SCHEMBL20243386 0.77 CAMK2D (0.55) CAMK2DPRKCBPRKCAPRKCHPRKCE
SCHEMBL19217026 0.76 CAMK2D (0.50) CAMK2DPRKCBPRKCAPRKCHPRKCE
SCHEMBL19217028 0.75 GSK3B (0.51) CAMK2DPRKCBPRKCAPRKCHPRKCE
SCHEMBL5683160 0.74 GSK3B (0.56) CAMK2DPRKCBPRKCAPRKCHPRKCE
SCHEMBL9561901 0.73 CCR6 (0.56) CAMK2DCCR6HKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928465-B1 USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER CENTOGENE GMBH (DE) 2020-11-18 EP disclosed
US-10420754-B2 Use of maleimide derivatives for preventing and treating cancer CENTOGENE AG (DE) 2019-09-24 US disclosed
US-9993463-B2 Use of maleimide derivatives for preventing and treating cancer CENTOGENE AG (DE) 2018-06-12 US disclosed
US-9724331-B2 Use of maleimide derivatives for preventing and treating leukemia CENTOGENE AG (DE) 2017-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10420754-B2 Use of maleimide derivatives for preventing and treating cancer MGMT, IDH3A, CYP3A43 CAMK2D 4647/4885STK10 2436/4885SLK 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.